Sotatercept news

All news on Sotatercept (also known as WINREVAIR): plants, production capacities, investments and involved companies in Europe.

30 September 2025
Merck's WINREVAIR Reduces PAH Clinical Worsening Risk by 76% in Phase 3 Trial
WINREVAIR, when started within a year of PAH diagnosis, significantly lowers clinical worsening risk. Safety profile aligns with previous trials. Results shared at ERS 2025 and published in NEJM.

Who will be producing Sotatercept in the future?

Find out with chemXplore Analytics